Intra-Cellular To Present Part 1 Data Of Phase 1/2 Trial For ITI-007 At ANA

(RTTNews) - Intra-Cellular Therapies, Inc. (ITCI) Monday said said it will present data from part 1 of its Phase 1/2 clinical trial for ITI-007 at the American Neurological Association annual meeting. 

The company said initial results indicated that ITI-007 met primary objectives of the study on healthy geriatric subjects. The results also showed a dose-related pharmacokinetic profile in elderly subjects.

Safety and tolerability, and pharmacokinetic data were determined as the primary and secondary outcome measures, the company said.

Furthermore, the company found that dosage of ITI-007 upto 10 mg improved sleep in insomniacs. Intra-Cellular said this indicates that low doses of ITI-007 show proof-of-mechanism by engaging key brain areas.